Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis

What is it about?

Long-acting antipsychotics are recognized as a valuable option for preventing relapse in people with schizophrenia, however, there is uncertainty on which of these medications are the most effective and acceptable. This network meta-analysis included 78 randomized trials (comprising 11,505 individuals) in order to compare long-acting antipsychotics between each other. Most of them showed a similar profile, however, those supported by the most reliable data in terms of both relapse prevention and all-cause treatment discontinuation (indicated as "acceptability") were paliperidone-LAI 3- and 1-monthly, aripiprazole-LAI, and olanzapine-LAI.

Featured Image